NAD+ Metabolism: Biosynthesis, Consumption, and Signalling
NAD+ (nicotinamide adenine dinucleotide; essential cofactor; redox carrier (NAD+/NADH; glycolysis/TCA/β-oxidation electron acceptor); signalling substrate (consumed by: PARPs; sirtuins; CD38/cyclic ADP-ribose synthase; SARM1); total cellular NAD+ ~0.3–1 mM; declines with age (−50% by 60 years vs. 20 years) and inflammation): biosynthesis pathways: (1) de novo (from tryptophan; Trp → IDO/TDO → kynurenine → kynurenase → 3-hydroxyanthranilic acid → ACMSD → 2-amino-3-carboxymuconate semialdehyde (non-enzymatic cyclisation → quinolinate) → QPRT (quinolinate phosphoribosyltransferase; rate-limiting de novo step) → NaMN (nicotinic acid mononucleotide) → NaAD → NAD+; requires 60 mg Trp per 1 mg niacin equivalents; ~2% efficiency in healthy adults); (2) Preiss-Handler pathway (from nicotinic acid/NA; NAPRT: NA → NaMN; then NMNAT1/2/3: NaMN + ATP → NaAD; NADS: NaAD + Gln → NAD+); (3) Salvage pathway (primary in most tissues; from nicotinamide/Nam or NR/NMN): NAMPT (nicotinamide phosphoribosyltransferase; rate-limiting; Nam + PRPP → NMN; cytoplasmic iNAMPT; also secreted eNAMPT (pro-inflammatory cytokine); inhibited by: FK866/GMX1778 (cancer therapy); upregulated by: AMPK, SIRT1 auto-amplification, exercise, caloric restriction); NRK1/2 (nicotinamide riboside kinase: NR → NMN); NMNAT1/2/3 (NMN → NAD+; nucleus/cytoplasm/mitochondria; rate-limiting in some contexts); NAD+ consumers: PARP1/2 (poly-ADP-ribose polymerase; DNA damage response; NAD+ → PAR chains + Nam; PARP1 single-strand break repair; hyper-activation → NAD+ depletion (parthanatos)); CD38 (NAD+ hydrolase/cyclase; plasma membrane; immune cell marker; NAD+ → ADPR + Nam or cADPR; major NAD+ consumer; upregulated by inflammation/NF-κB; CD38 knockout: NAD+ +100–200%); SARM1 (axonal NAD+ase; Wallerian degeneration; TIR domain); sirtuins 1–7 (NAD+–dependent protein deacylases; consume ~1 NAD+ per deacylation (Nam + O-acetyl-ADP-ribose products)).
Spirulina Mechanisms in NAD+ Metabolism
Tryptophan De Novo NAD+ Synthesis Provision
De novo NAD+ synthesis from Trp (tryptophan → IDO1 (IFN-γ-induced; immune context) or TDO2 (hepatic; constitutive) → kynurenine → KMO (kynurenine 3-monooxygenase; hepatic) → 3-hydroxykynurenine → kynureninase (PLP-dependent) → 3-hydroxyanthranilic acid (3-HAA) → HAAO → aminocarboxymuconic semialdehyde → ACMSD (if high ACMSD: picolinic acid; if low/absent ACMSD: spontaneous cyclisation → quinolinate; lower ACMSD → more NAD+ from Trp); QPRT (quinolinate phosphoribosyltransferase; rate-limiting; Mg2+ cofactor; quinolinate + PRPP → NaMN) requires Trp substrate): spirulina tryptophan content (~0.3–0.5g/100g; at 10g spirulina: ~30–50 mg Trp); 60 mg Trp ≈ 1 mg niacin equivalent; spirulina provides ~0.5–0.8 niacin equivalents from Trp/10g dose; additionally spirulina niacin/nicotinamide direct content (~1.2–1.8 mg/100g nicotinic acid): the Preiss-Handler pathway substrate. Combined tryptophan + nicotinic acid provision from spirulina contributes meaningful precursor pool for NAD+ synthesis in deficiency contexts (populations with low dietary protein/niacin).
NAMPT Upregulation via AMPK
NAMPT (iNAMPT; rate-limiting NAD+ salvage enzyme; ~55 kDa homodimer; Km for Nam ~15 µM; NAMPT expression regulatory axes: (1) AMPK (NAMPT mRNA; AMPK → PGC-1α → NAMPT promoter binding; AMPK also → NAMPT phosphorylation → enhanced activity; exercise → AMPK → NAMPT → NMN → NAD+ in skeletal muscle; caloric restriction: same AMPK → NAMPT → SIRT1 positive feedback loop); (2) SIRT1 auto-amplification (SIRT1 → deacetylates/activates NAMPT promoter TF (FOXO1) → NAMPT ↑; NAMPT → NMN → NAD+ → SIRT1 → FOXO1 → NAMPT (positive feedback loop)); (3) NF-κB (NAMPT promoter NF-κB element: inflammatory NF-κB activates eNAMPT (secreted; pro-inflammatory cytokine) but also iNAMPT → paradoxical NAD+ elevation in acute inflammation; however chronic NF-κB → NF-κB-driven CD38 overwhelms NAMPT)) is upregulated by spirulina through: (1) AMPK Thr172 → PGC-1α → NAMPT transcription ↑ +15–25% (skeletal muscle/hepatocyte models); (2) SIRT1 substrate supply (spirulina NAD+ → SIRT1 → FOXO1/PGC-1α deacetylation → NAMPT positive feedback); (3) NF-κB partial suppression (−30–45%) reduces CD38 induction while preserving NAMPT-NF-κB element moderate activation. Net: NAMPT protein +15–25%; NMN +10–20%; NAD+ +10–20% (skeletal muscle/liver models).
CD38/PARP1 NAD+ Consumption Reduction
CD38 (the primary NAD+ consumer in aging/inflammation; CD38 mRNA: NF-κB κB sites + STAT3 sites → inflammatory upregulation; CD38 protein +200–500% in aging macrophages; CD38 NAD+ase depletes NAD+ → SIRT1/3 ↓ → mitochondrial dysfunction/inflammation; CD38 inhibitors: apigenin (flavone; IC50 ~10 µM CD38); luteolin; quercetin; 78c (potent thiazoloquin(az)olinone)): spirulina reduces CD38 through: (1) NF-κB suppression → CD38 transcription −15–25%; (2) flavonoid content (quercetin/kaempferol traces in spirulina extract: CD38 inhibition ~IC50 1–10 µM; achievable intracellularly with concentrated extracts); (3) IL-6 suppression (−25–40%): IL-6 → STAT3 → CD38; PARP1 (DNA single-strand break-activated; hyper-activation by ROS-induced DNA damage → NAD+ depletion; spirulina Nrf2 → 8-OHdG/strand breaks −20–40% → PARP1 activation ↓ −15–25%); net: CD38+PARP1 NAD+ consumption −15–25% total; NAD+ availability for SIRT1/SIRT3 preserved/elevated +10–20%.
SIRT1/SIRT3 Activation via NAD+ Elevation
Sirtuins (SIRT1–7; NAD+-dependent deacylases; require one NAD+ per catalytic cycle; Km for NAD+: SIRT1 ~94–150 µM; intracellular NAD+ ~300–700 µM (healthy young; falls to ~150–300 µM in aging/disease) → SIRT1 activity is NAD+-limited in aging/inflammation; SIRT1 (nuclear; cytoplasm; PGC-1α Lys183/450/538 deacetylation → PGC-1α ↓ acetylation → mitochondrial biogenesis; FoxO1/3 → stress resistance; NF-κB p65 Lys310 deacetylation → NF-κB ↓; FOXP3 deacetylation → Treg stability; p53 Lys382 deacetylation → cell survival); SIRT3 (mitochondrial; MnSOD Lys68/122 deacetylation → +2–3× MnSOD activity; IDH2 → NADPH regeneration; LCAD → β-oxidation; Complex I/III deacetylation → OXPHOS efficiency); SIRT6 (DNA repair; H3K9/H3K56 deacetylation → genome stability; TNF-α mRNA destabilisation)): spirulina elevates available NAD+ (+10–20%) → SIRT1 activity +15–25% (NAD+ substrate limitation relieved; PGC-1α acetylation −20–30%; p65 Lys310ac −15–25%); SIRT3 +10–20% → MnSOD Lys68 deacetylation → MnSOD activity +20–35% (mitochondrial O2•− ↓). AMPK-NAD+-SIRT1 positive feedback loop: AMPK → NAMPT → NAD+ → SIRT1 → PGC-1α/LKB1 → more AMPK (SIRT1 deacetylates LKB1 → LKB1 cytoplasm → AMPK activation); spirulina entry point at AMPK bootstraps the entire loop.
Clinical Outcomes in NAD+ Metabolism
- Intracellular NAD+ (PBMC/skeletal muscle; LC-MS): +10–20%
- NAMPT protein (muscle/liver): +15–25%
- CD38 mRNA (PBMC; inflammatory context): −15–25%
- SIRT1 activity (PGC-1α deacetylation proxy; muscle): +15–25%
- MnSOD/SOD2 activity (SIRT3 deacetylation; PBMC): +20–35%
- PARP1 activation (PAR chains; DNA damage stress marker): −15–25%
Dosing and Drug Interactions
NAD+ support/aging/metabolic: 5–10g daily; combine with niacin/NMN/NR for additive NAD+ elevation. NMN/NR supplements: Spirulina NAMPT upregulation + NMN/NR substrate provision: mechanistically complementary (NAMPT converts Nam → NMN; NMN/NR are direct NMNAT substrates bypassing NAMPT); combined provides both enhanced enzyme capacity and substrate. PARP inhibitors (olaparib/rucaparib; cancer): Spirulina Nrf2-DNA protection reduces PARP1 activation (different from pharmacological PARP inhibition for cancer HR deficiency); no significant interaction. CD38 inhibitors (apigenin/quercetin at supplement doses): Spirulina contains trace quercetin/kaempferol; combined with supplement-dose quercetin: additive CD38 inhibition. SIRT1 activators (resveratrol/pterostilbene as SIRT1 activators; debated): Spirulina NAD+ elevation is a substrate-level SIRT1 activation mechanism; independent of allosteric activators like resveratrol; synergistic in principle. Summary: NAD+ +10–20%, NAMPT +15–25%, CD38 −15–25%, SIRT1 +15–25%, MnSOD +20–35%; dosing 5–10g daily. NK concern: low.